Clinical Trials

Several clinical trials incorporate saccharin into phase-not-applicable diagnostic protocols to evaluate gustatory and mucociliary clearance pathways in physiological and respiratory conditions. These investigations—sponsored by institutional and corporate entities such as St. Paul's Hospital Canada, RAI Services Company, and Philip Morris Products S.A.—focus on chronic rhinosinusitis, smoking cessation biomarkers, and mucociliary function in smokers versus non-smokers. Recruitment statuses for these trials range from completed to unknown.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04278950 Unknown status
Chronic Rhinosinusitis (Diagnosis)
St. Paul''s Hospital Canada
2020-02-10 Not Applicable
NCT04979013 Completed
Smoking|Smoking Cessation|Tobacco Use
RAI Services Company
2019-05-30 Not Applicable
NCT03086707 Completed
Smokers|Never Smokers
Philip Morris Products S.A.
2017-01-21 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Saccharin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Saccharin binds to and activates the TAS1R2/TAS1R3 sweet taste receptor complex, triggering G protein-coupled intracellular cascades that produce a strong gustatory sweet signal without altering carbohydrate metabolism. This rapid sensory readout allows saccharin to function as a non-metabolized diagnostic tracer, facilitating the clinical assessment of nasal mucociliary clearance velocity in patients evaluated for chronic rhinosinusitis or smoking-induced respiratory alterations.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.